Project Details
Projekt
Understanding and breaking proteasome inhibitor resistance in multiple myeloma patients (A12)
Subject Area
Hematology, Oncology
Term
since 2024
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 514894665
Multiple myeloma (MM) is the second most common hematological malignancy. Initially, patients respond well to protease inhibitors (PIs) but eventually all relapse. Thus far, the mechanisms that underlie PI resistance are poorly understood. This project aims to (i) understand shared and distinct mechanisms of action of the PIs BTZ, CFZ and IXA in the treatment of MM and (ii) develop strategies to re-sensitize PI-resistant disease. This will be achieved by: i) improving primary MM cell culture and low cell number proteomics, ii) proteomic and epigenomic profiling of patients and iii) phenotypic drug combination screening and mechanism of action elucidation in primary MM cells.
DFG Programme
CRC/Transregios
Applicant Institution
Technische Universität München (TUM)
Project Heads
Professor Dr. Martin Kortüm; Professor Dr. Bernhard Küster
